Last week, Upfront Diagnostics was one of four companies invited to pitch at a Parliamentary Reception at the House of Commons alongside 150 members of the British In Vitro Diagnostics Association (BIVDA).
The past few years have taught us that our industry needs to build a healthcare system that is able to diagnose patients anywhere and at any time. Point-of-care will play a key role in making this happen.
The event was a valuable opportunity for our CEO, Gonzalo Ladreda, to present the potential of our "LVOne" technology to MPs, members of government agencies and the NHS, and key stakeholders in the industry. LVOne, our stroke blood test, is an accessible, straightforward, convenient device that has the potential to change the quality of life for 5,000 UK stroke patients and save millions every year.
A special thank you to Dr Pooja Sikka, our longstanding partner from APEX Ventures; Helen Dent, the COO of BIVDA; Maggie Throup MP; Chi Onwurah MP, Shadow Minister for Science, Research, and Innovation; Professor Sir Stephen Powis, Medical Director of NHS England; and our fellow innovators from ACT-IVD, AMLo Biosciences, Veracyte, Inc., and genedrive.
Story by Upfront Diagnostics
Comments